Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Kura Oncology (KURA) Income towards Parent Company: 2010-2024

Historic Income towards Parent Company for Kura Oncology (KURA) over the last 7 years, with Dec 2024 value amounting to -$174.0 million.

  • Kura Oncology's Income towards Parent Company fell 36.23% to -$74.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$214.9 million, marking a year-over-year change of. This contributed to the annual value of -$174.0 million for FY2024, which is 13.99% down from last year.
  • According to the latest figures from FY2024, Kura Oncology's Income towards Parent Company is -$174.0 million, which was down 13.99% from -$152.6 million recorded in FY2023.
  • In the past 5 years, Kura Oncology's Income towards Parent Company registered a high of -$135.8 million during FY2022, and its lowest value of -$174.0 million during FY2024.
  • For the 3-year period, Kura Oncology's Income towards Parent Company averaged around -$154.2 million, with its median value being -$152.6 million (2023).
  • Data for Kura Oncology's Income towards Parent Company shows a maximum YoY fell of 13.99% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Kura Oncology's Income towards Parent Company stood at -$135.8 million in 2022, then fell by 12.36% to -$152.6 million in 2023, then decreased by 13.99% to -$174.0 million in 2024.